AVLN (Avalyn Pharma) Shares Buyback Ratio %: 0.00 (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
12 GF Score
Price $31.35
View Full Analysis

What is Avalyn Pharma Shares Buyback Ratio %?

Avalyn Pharma AVLN -5.63% 12 Shares Buyback Ratio % is 0.00 as of Sep. 20, 2026. GuruFocus rates AVLN with a GF Score™ of 12/100.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Avalyn Pharma's current shares buyback ratio was 0.00%.

Avalyn Pharma Shares Buyback Ratio % Related Terms

Avalyn Pharma Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Shares Buyback Ratio % Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Shares Buyback Ratio %
- 0.00

Avalyn Pharma Quarterly Data
Mar25 Jun25 Mar26 Jun26
Shares Buyback Ratio % - 0.00 0.00 0.00
AVLN
12GF Score
Avalyn Pharma Inc AVLN
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Shares Buyback Ratio % Calculation

Avalyn Pharma's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(44.333095 - 44.333095) / 44.333095
=0.00%

Avalyn Pharma's Shares Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2026 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Mar. 2026 )
=(44.333095 - 44.333094) / 44.333095
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 0.00 mean?
Avalyn Pharma (AVLN) has a Shares Buyback Ratio % of 0.00 as of Sep. 20, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Avalyn Pharma and its competitors.
Is Avalyn Pharma's Shares Buyback Ratio % too high?
Avalyn Pharma's current Shares Buyback Ratio % is 0.00. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Shares Buyback Ratio % compare to LBRX and LTGO?
Avalyn Pharma's Shares Buyback Ratio % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current Shares Buyback Ratio % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Shares Buyback Ratio % of 0.00. The current Shares Buyback Ratio % is 0.00. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Shares Buyback Ratio % is 0.00 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score

Get the complete analysis for AVLN

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.35
Price